Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 26, Issue 6, Pages 624-639Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458519872751
Keywords
Multiple sclerosis; optical coherence tomography; clinical utility; clinical trials
Categories
Funding
- Genentech Corporation
- Biogen Idec
- MedDay Pharmaceuticals
Ask authors/readers for more resources
Optical coherence tomography (OCT) has emerged as a fast, non-invasive, inexpensive, high-resolution imaging technique in multiple sclerosis (MS). Retinal layer quantification by OCT facilitates a 'window' into not only local retinal pathology but also global neurodegenerative processes, recognised to be the principal substrates of disability accumulation in MS. While OCT measures in MS have been demonstrated to reflect visual function, inflammatory activity outside of the visual pathways, disability measures including the prediction of disability progression, whole brain atrophy, and the differential neuroprotective effects of disease-modifying therapies, debate continues regarding the clinical utility of OCT in everyday practice. This review presents an overview of the evidence supporting OCT, with particular focus on its application in the MS clinic. We will also discuss the role of OCT in MS clinical trials to develop novel neuroprotective and potential remyelinating therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available